Life Insurance for IgA Nephropathy

Being diagnosed with IgA nephropathy—also known as Berger’s disease—can raise immediate concerns about kidney function, long-term stability, and how to protect your family financially. One of the most common questions we hear is whether life insurance is still available, whether it will be affordable, and whether the diagnosis automatically triggers a decline. The good news is that many people with IgA nephropathy can still qualify for life insurance. Underwriting outcomes are driven far more by measurable kidney health than by the diagnosis name alone. When lab trends are stable, blood pressure is controlled, and proteinuria is low or improving, fully underwritten term or permanent life insurance can be realistic. When the disease is more advanced or labs show declining function, coverage may still be possible—often with higher ratings or with coverage structured differently. At Diversified Insurance Brokers, we take a case-by-case underwriting approach for kidney conditions. Instead of relying on one insurer’s appetite, our advisors match your profile with carriers that evaluate renal histories more reasonably and that focus on objective metrics—like eGFR trends and treatment stability—rather than blanket assumptions.

What Is IgA Nephropathy?

IgA nephropathy is an immune-mediated kidney disorder where immunoglobulin A (IgA) deposits build up in the kidney’s filtering units (glomeruli). Over time, that inflammation can interfere with filtration and, in some cases, contribute to chronic kidney disease (CKD). The key point is that progression varies widely. Some people remain stable for decades with minimal loss of function, while others develop higher proteinuria, worsening blood pressure, and declining eGFR. IgA nephropathy is the most common primary glomerular disease in the world, and because its clinical spectrum runs from entirely benign to progressively severe, underwriters cannot treat it as a single risk category. From a life insurance underwriting perspective, this is exactly why the diagnosis alone does not determine insurability. Underwriters are primarily evaluating whether your kidneys are functioning well today, how stable the trend has been over time, and whether there are signs of accelerating progression or complications. For a broader overview of how pre-existing conditions are handled across life insurance underwriting, start with our guide on life insurance with pre-existing conditions.

How Life Insurance Underwriters Evaluate IgA Nephropathy

For IgA nephropathy, carriers focus on objective data. The strongest applications tell a clear “trend story” that an underwriter can verify quickly. In most cases, that means stable labs over time, controlled blood pressure, and documentation that the condition is being followed appropriately by a nephrologist. Understanding which specific metrics underwriters focus on—and how each one affects outcomes—gives applicants a clearer picture of what to expect before any application is submitted.

Kidney function and trend are the most fundamental evaluation factors. Underwriters look at creatinine and—most importantly—the estimated glomerular filtration rate (eGFR). A single eGFR reading matters, but the direction matters more. Stable results across multiple years can significantly improve outcomes versus a file with a downward trend. Proteinuria and albumin levels are equally critical: protein in the urine is a major risk marker in IgA nephropathy. Carriers will often request the most recent urine microalbumin or protein results and may compare them to prior years. Lower levels—or levels that have improved with treatment—are typically viewed more favorably. Blood pressure management also weighs heavily, since hypertension can accelerate kidney decline. Insurers pay close attention to BP control and medication compliance. Many applicants with renal conditions are treated with ACE inhibitors or ARBs, and underwriters generally like seeing a consistent, well-managed regimen. Our page on life insurance for high blood pressure explains how control and stability influence rate class independently.

Complications and comorbidities round out the underwriting picture. Underwriters look for related risks that can change the overall profile—such as diabetes markers, cardiovascular disease, or evidence of advanced CKD. If complications are present, the case becomes about the full health picture, not just IgA nephropathy in isolation. Consistent nephrology care, clear treatment notes, and documented stability reduce carrier hesitation. If records show gaps in follow-up or uncertainty about progression, carriers tend to be more conservative. For context on how carriers gather labs and records during underwriting, see what to expect during a life insurance exam.

eGFR Ranges and Typical Underwriting Outcomes

eGFR alone does not determine underwriting outcome — trend stability, proteinuria levels, blood pressure, and comorbidities all contribute to the final evaluation. These ranges represent general patterns, not guaranteed outcomes. Always work with an experienced independent life insurance broker before drawing conclusions about individual eligibility.

What Often Leads to Better Rate Classes

Most people with IgA nephropathy don’t need a perfect file to qualify, but there are consistent factors that tend to improve approvals and pricing. Underwriters generally respond best when the case shows predictable stability rather than uncertainty. Stable or improving lab trends tend to move outcomes in the right direction—especially stable eGFR across multiple years and lower proteinuria. Controlled blood pressure and a consistent medication routine show that risk is being managed proactively. Applicants who are non-smokers with a healthier build and no major related conditions often see better offers than applicants where multiple risk factors stack together.

Because carriers vary widely in how aggressively they “stack” risk, the broker strategy matters as much as the underlying health profile. One insurer may heavily penalize a moderate A1C or elevated BP alongside kidney impairment, while another carrier may price the same profile more reasonably when the kidney trend is stable. This is why we typically pre-screen IgA nephropathy cases before choosing where to submit. Presenting to the wrong carrier first—even with a favorable profile—can result in a decline that complicates future submissions and may trigger more scrutiny from subsequent carriers. Protecting insurability by getting the carrier match right the first time is one of the most valuable things an experienced high-risk broker can do. See our high-risk life insurance services overview for how we approach medically complex cases more broadly, and our resource on how to get life insurance with health issues for the general approach to managing the application process when a condition is present.

Life Insurance Options for IgA Nephropathy

Many applicants with IgA nephropathy are eligible for fully underwritten term life insurance, especially when kidney function is stable and complications are not present. Preferred categories can be harder to reach with renal histories, but standard or table-rated approvals are common when labs are supportive. Term coverage is often the most cost-effective way to protect income, family obligations, and time-bound needs—a 20-year term for someone in their 40s, for example, covers the years when dependents are most financially exposed without the long-term commitment of a permanent policy. For context on how table ratings work and what they mean in dollar terms, see our life insurance table ratings explained guide.

Permanent life insurance may also be available for stable cases, depending on age, kidney metrics, and the rest of the applicant’s profile. Permanent coverage can be a fit when long-term needs are the priority—estate planning, lifelong dependents, or final expense planning. Underwriting for permanent policies still relies on the same kidney metrics, so the stability story remains central. When kidney impairment is more advanced—or the case includes multiple compounding risks—coverage may still be possible but structured differently. In those situations, simplified-issue options for smaller face amounts, or a layered approach combining a smaller simplified-issue policy with a larger underwritten policy, may be the right path. For cases where traditional coverage is not available at all, burial insurance for people with kidney disease remains a meaningful option that provides guaranteed coverage without medical underwriting for final expense amounts.

If You’ve Already Been Declined

A prior decline from one carrier is not the final word. Carriers evaluate IgA nephropathy differently—some take more conservative positions by default, while others specialize in renal risk and make more data-driven decisions when trends are stable. Being declined by one insurer does not change your underlying health profile; it only means that particular carrier’s underwriting guidelines didn’t accommodate your specific combination of factors. Working with a broker who understands the impaired-risk market and has access to multiple carriers with different appetites for kidney cases significantly improves the chance of finding a viable approval after an initial decline.

The key steps after a decline: document what was on the application, understand what the carrier cited as the decline reason, and then approach a different carrier through an independent broker who can pre-screen the case and match it to carriers known to be more flexible with stable renal histories. Never apply broadly to multiple carriers simultaneously after a decline—each application generates a record that subsequent carriers can see, and a string of denials creates a pattern that makes future approvals harder. Our resource on life insurance with a prior decline explains how to navigate this situation and what strategies typically produce the best outcomes.

Why a Kidney-Specific Underwriting Review Matters

Kidney cases are not an area where “submit and hope” works well. Carriers differ dramatically in how they treat IgA nephropathy. Some insurers take an overly conservative stance by default, while others take a more data-driven approach when trends are stable. Submitting to the wrong carrier first can lead to a decline that complicates future submissions—especially if the decline triggers more scrutiny or additional requirements from subsequent insurers. That’s why we use a kidney-specific review strategy: a targeted questionnaire that clarifies the details that actually drive underwriting. This includes current eGFR, how long the trend has been stable, presence and level of proteinuria, blood pressure control, medication regimen, any biopsy confirmation or specialist notes, and whether there has been progression toward later-stage CKD. When the file is packaged correctly, carriers can make a cleaner decision with fewer delays. This approach protects insurability, reduces wasted time, and helps ensure you’re presented to the most appropriate insurers from the start—rather than letting the first carrier define your outcome.